May. 22 at 4:09 PM
$PTN $RYTM $VKTX $LLY
Flagging that Palatin’s (
$PTN) uplisting to Nasdaq on May 29th is a major structural catalyst the market is completely ignoring. AT a microscopic
$26M market cap, the stock is deeply disconnected from its underlying asset value, largely because alternative exchanges like the NYSE American are completely walled off from major institutional healthcare funds and passive index mandates. Moving to the Nasdaq removes these compliance barriers, creating an automated pipeline of non-discretionary buying that could easily drive a 40% to 75% mechanical upward re-rating as the new bid enters a highly illiquid order book. If this newfound institutional demand triggers a short squeeze among trapped bears alongside a retail momentum chase, the upside potential quickly stretches to 100%–180% as the free float gets entirely locked up. For patient investors tracking the next-gen obesity landscape, the current valuation is a screaming buy ahead of next Friday's opening bell IMO.
